Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Edgewise Therapeutics’ Phase 2 HCM data put systolic function into sharper focus

Find out how Edgewise Therapeutics’ EDG-7500 data could reshape HCM drug development as Phase 3 questions emerge.

Read More
Pharma & Biotech

Why Lilly is betting on peripheral pain biology with the 4E Therapeutics acquisition

Find out how Lilly’s 4E Therapeutics deal could advance non-opioid chronic pain drugs and what risks remain.

Read More
Pharma & Biotech

Qihan Biotech gains FDA momentum for QT-019B as allogeneic CAR-T ambitions grow

Find out how Qihan Biotech’s QT-019B FDA designations could reshape autoimmune CAR-T development and what risks remain.

Read More
Representative image showing a sleep medicine consultation as Takeda’s oveporexton data highlight a potential shift in narcolepsy type 1 care.
Pharma & Biotech

Takeda’s narcolepsy data reveal why orexin agonists are becoming a neuroscience priority

Find out how Takeda’s oveporexton data could reshape narcolepsy type 1 care as approval, safety and access questions loom.

Read More
Representative image of a pediatric mobility assessment, highlighting how cTAP’s new Duchenne muscular dystrophy prognostic score could help predict loss of ambulation and improve DMD trial design.
Pharma & Biotech

Could cTAP’s new Duchenne prognostic score change how DMD trials measure mobility risk?

Find out how cTAP’s Duchenne prognostic score could improve DMD trial design and loss of ambulation prediction.

Read More
A sterile ophthalmic vial in an eye exam setting highlights Saptalis Pharmaceuticals’ Cyclosporine Ophthalmic Emulsion 0.05% launch and growing generic dry eye treatment access. Representative image.
Pharma & Biotech

Can Saptalis Pharmaceuticals strengthen dry eye access with cyclosporine launch?

Find out how Saptalis Pharmaceuticals’ cyclosporine launch could reshape access, competition and generic dry eye treatment.

Read More
Representative image of an HIV prevention consultation, as Gilead Sciences’ once weekly oral Yeztugo filing puts long acting PrEP and future FDA review in focus.
Pharma & Biotech

Gilead’s once weekly Yeztugo bid could challenge the old daily pill versus injection divide

Read how Gilead’s once weekly oral Yeztugo filing could reshape HIV prevention, PrEP adherence and long acting therapy competition.

Read More
Representative image: Kalohexis’ 710GO obesity drug research highlights how dual MC3R/MC4R activation could reshape oral weight loss therapy beyond GLP-1 medicines.
Pharma & Biotech

Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead

Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.

Read More
Representative image of an endocrinology researcher reviewing adrenal hormone data, as Neurocrine Biosciences’ Crenessity update at ENDO 2026 raises new questions about treatment options for classic congenital adrenal hyperplasia.
Pharma & Biotech

Could Crenessity move beyond 21-hydroxylase CAH after Neurocrine’s ENDO 2026 data?

Find out how Neurocrine’s Crenessity data could expand rare CAH treatment thinking while key clinical questions remain.

Read More
Representative image: A pediatric rare disease consultation highlights how VYKAT XR data could reshape long-term hyperphagia treatment in Prader-Willi syndrome.
Pharma & Biotech

Soleno Therapeutics VYKAT XR data strengthens long-term case in Prader-Willi syndrome

Find out how Soleno Therapeutics’ VYKAT XR data could reshape hyperphagia treatment in Prader-Willi syndrome.

Read More